Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 2/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413018 | 1.00 | LMNA (0.48) | LMNAMAPTHTTBLMITGB2 | |
| SCHEMBL13182219 | 0.91 | NPC1 (0.44) | LMNAMAPTHTTBLMITGB2 | |
| SCHEMBL31151216 | 0.85 | CYP3A4 (0.54) | MAPTGAAPOLBSMN1; SMN2NPC1 | |
| SCHEMBL3117045 | 0.85 | CYP3A4 (0.54) | MAPTGAAPOLBSMN1; SMN2NPC1 | |
| SCHEMBL29650705 | 0.79 | PRKCI (0.52) | MAPTADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL1007568 | 0.79 | PRKCI (0.52) | MAPTADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL1669250 | 0.76 | CHRM2 (0.41) | MAPTITGB2ICAM1ITGALADRA2A | |
| SCHEMBL753333 | 0.76 | DYRK1A (0.46) | ADRA2AADRA2BADRA2CDYRK1ADYRK2 | |
| SCHEMBL29584645 | 0.76 | DYRK1A (0.46) | ADRA2AADRA2BADRA2CDYRK1ADYRK2 | |
| SCHEMBL3797296 | 0.76 | ACACB (0.36) | POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939829-B | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-112939829-A | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-108017557-B | Cyanidation method for preparing nitrile compound | 中国科学院兰州化学物理研究所苏州研究院 | 2020-11-24 | — | — | CN | claimed |
| US-12624022-B2 | Heterocyclic immunomodulators as PDL1 checkpoint inhibitor | Janssen Sciences Ireland Unlimited Company (IE) | 2026-05-12 | — | — | US | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024129601-A1 | COMPOUND EMBODIMENTS FOR MUSCLE MYOSIN INHIBITION AND METHODS OF MAKING AND USING THE SAME | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIV. OF NEVADA (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-3980413-B1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3980413-B1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-07-19 | — | — | EP | disclosed |
| EP-1490350-A1 | PYRANON AND PYRANDION INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE | PFIZER INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004081531-A9 | LIGAND ANALYSIS | NEOGENESIS PHARMACEUTICALS INC (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087156-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004080463-A1 | HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004081531-A2 | LIGAND ANALYSIS | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20030195239-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003082848-A1 | PYRANON AND PYRANDION INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE | PFIZER INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-6448433-B1 | REACTING AN ORGANIC HALIDE WITH TETRAHYDROXYDIBORON; GROUP 8-11 METAL CATALYST | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624022-B2 | Heterocyclic immunomodulators as PDL1 checkpoint inhibitor | CD274, PDCD1, PDCD1LG2 | LMNA 2883/4885MAPT 2477/4885HTT 3885/4885 |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | LMNA 1479/4885MAPT 88/4885HTT 2213/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | LMNA 1479/4885MAPT 88/4885HTT 2213/4885 |
| US-20030195239-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | LMNA 3489/4885MAPT 2903/4885HTT 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.